Loading
A phase 3 trial of Lurbinectedin, FOLFIRI, Topotecan in small-cell lung cancer, run by Luye Pharma Group Ltd., now recruiting.
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC is a phase 3 interventional study registered as NCT06496048 by Luye Pharma Group Ltd., with 180 participants planned, started 2024-09-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: Lurbinectedin, Irinotecan, Lurbinectedin, Topotecan. Conditions listed: Relapsed Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Luye Pharma Group, Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Luye Pharma Group, FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Lurbinectedin, Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.